SCHEMBL4030138

SCHEMBL4030138

Cn1c(-c2ccco2)nc(C(=O)O)c(O)c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.57
FEN1 P39748 1/20 0.57
ERCC4 Q92889 1/20 0.57
LMNA P02545 1/20 0.46
HIF1A Q16665 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 6/20 0.43
RAB9A P51151 2/20 0.43
TSHR P16473 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032912 0.81 LMNA (0.44) LMNAHIF1ASMN1; SMN2TDP1L3MBTL1
SCHEMBL6018523 0.77 KCNE1 (0.54) ERCC1FEN1ERCC4LMNASMN1; SMN2
SCHEMBL6017808 0.76 MEN1 (0.45) LMNASMN1; SMN2ALDH1A1RAB9AKDM4E
SCHEMBL6017762 0.74 MEN1 (0.53) LMNASMN1; SMN2ALDH1A1MAPTPKM
SCHEMBL6017670 0.74 MEN1 (0.44) LMNAALDH1A1TP53MAPTPKM
SCHEMBL4031399 0.73 ERCC1 (0.49) ERCC1FEN1ERCC4LMNASMN1; SMN2
SCHEMBL4031394 0.73 ERCC1 (0.49) ERCC1FEN1ERCC4LMNASMN1; SMN2
SCHEMBL4032042 0.73 ERCC1 (1.00) ERCC1FEN1ERCC4LMNASMN1; SMN2
SCHEMBL4030768 0.73 ERCC1 (0.57) ERCC1FEN1ERCC4LMNAALDH1A1
SCHEMBL4027375 0.72 L3MBTL1 (0.49) LMNASMN1; SMN2L3MBTL1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1470113-B1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ANGELETTI P IST RICHERCHE BIO (IT) 2009-01-07 EP claimed
US-20050130997-A1 Pyrimidinone viral polymerase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2005-06-16 US claimed
EP-1470113-B1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ANGELETTI P IST RICHERCHE BIO (IT) 2009-01-07 EP disclosed
US-20050130997-A1 Pyrimidinone viral polymerase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2005-06-16 US disclosed
EP-1470113-A1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2004-10-27 EP disclosed
WO-2003062211-A1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130997-A1 Pyrimidinone viral polymerase inhibitors POLR2A, POLR1E, POLR2E ERCC1 3181/4885FEN1 343/4885ERCC4 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.